Icosavax keeps up the excitement for its VLP 'soccer balls,' earning the RA Capital stamp of approval in $100M Series B

Max Gelman

Senior Editor

Roughly a year and a half since its last raise, Icosavax scored a fresh goal Wednesday morning in nabbing new funds for its soccer ball-like VLP vaccine tech. And the Seattle-based company is bringing in a high-profile set of new investors.

Icosavax unveiled a $100 million Series B, backed by Peter Kolchinsky’s RA Capital Management and Perceptive Advisors, among others. Kolchinsky scores a board seat with the raise, as the biotech plans to use its newfound cash to advance a handful of vaccine programs for SARS-CoV-2 and viruses that trigger pneumonia.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Icosavax keeps up the excitement for its VLP 'soccer balls,' earning the RA Capital stamp of approval in $100M Series B

Max Gelman

Senior Editor

Unlock this article instantly by becoming a free subscriber.

Autoimmune patients in CAR-T study see striking improvements across lupus and other diseases

As cash runs tight, bluebird plunges after pricing sickle cell gene therapy well above competitor and failing to win ...

Roche partner touts early allogeneic CAR-T data at #ASH23, but durability remains key question

FDA approves two gene therapies for sickle cell disease, including first that uses CRISPR

How one lab's decadeslong search for the 'holy grail' of sickle cell led to the first CRISPR therapy

Solid Tumors: The Next Frontier of Cancer Immuno-therapy

Icosavax keeps up the ex­cite­ment for its VLP 'soc­cer balls,' earn­ing the RA Cap­i­tal stamp of ap­proval in $100M Se­ries B

Max Gelman

Senior Editor

Unlock this article instantly by becoming a free subscriber.

Au­toim­mune pa­tients in CAR-T study see strik­ing im­prove­ments across lu­pus and oth­er dis­eases

As cash runs tight, blue­bird plunges af­ter pric­ing sick­le cell gene ther­a­py well above com­peti­tor and fail­ing to win ...

Roche part­ner touts ear­ly al­lo­gene­ic CAR-T da­ta at #ASH23, but dura­bil­i­ty re­mains key ques­tion

FDA ap­proves two gene ther­a­pies for sick­le cell dis­ease, in­clud­ing first that us­es CRISPR

How one lab's decades­long search for the 'holy grail' of sick­le cell led to the first CRISPR ther­a­py

Sol­id Tu­mors: The Next Fron­tier of Can­cer Im­muno-ther­a­py

Icosavax keeps up the excitement for its VLP 'soccer balls,' earning the RA Capital stamp of approval in $100M Series B

Autoimmune patients in CAR-T study see striking improvements across lupus and other diseases

As cash runs tight, bluebird plunges after pricing sickle cell gene therapy well above competitor and failing to win ...

Roche partner touts early allogeneic CAR-T data at #ASH23, but durability remains key question

FDA approves two gene therapies for sickle cell disease, including first that uses CRISPR

How one lab's decadeslong search for the 'holy grail' of sickle cell led to the first CRISPR therapy

Solid Tumors: The Next Frontier of Cancer Immuno-therapy